Schisandrin b prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of mapk/p53 signaling

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Thandavarayan, Rajarajan A ^a,b   Giridharan, Vijayasree V ^c   Arumugam, Somasundaram ^a   Suzuki, Kenji ^d   Ko, Kam Ming ^e   Krishnamurthy, Prasanna ^b   Watanabe, Kenichi ^a   Konishi, Tetsuya ^f,g  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c J K K NATTRAJA COLLEGE OF PHARMACY   (India)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^f Basic Studies on Second Generation Functional Foods NUPALS NUPALS Liaison R D Promotion Devision   (Japan)

^g CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CASPASE 3; DOXORUBICIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCHIZANDRIN B; 3-NITROTYROSINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYCLOOCTANE DERIVATIVE; LIGNAN; POLYCYCLIC HYDROCARBON; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDITIS; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; HEART; HEART FAILURE; HEART PROTECTION; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARDIOMYOPATHIES; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE FUNCTION; METABOLISM; PATHOPHYSIOLOGY;

MUS; RODENTIA; SCHISANDRA CHINENSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARDIOMYOPATHIES; CYCLOOCTANES; DISEASE MODELS, ANIMAL; DOXORUBICIN; GENE EXPRESSION REGULATION; LIGNANS; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; POLYCYCLIC COMPOUNDS; TYROSINE; VENTRICULAR FUNCTION, LEFT;

EID: 84929193360     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119214     Document Type: Article

References (52)

1. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997;11:931-936. PMID: 9337145
2. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene. 2004;23:7018-7030. PMID: 15273722
3. Thandavarayan RA, Watanabe K, Sari FR, Ma M, Lakshmanan AP, Giridharan VV, et al. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38alpha mitogen-activated protein kinase mice. Free RadicBiol Med. 49:1422-1431. doi: 10.1016/j.freeradbiomed.2010.08.005 PMID: 20705132
4. Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007;67:10428-10435. PMID: 17974986
5. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49:330-352. PMID: 17329180
6. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905. PMID: 9744975
7. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;11:1029-1033. PMID: 11038041
8. Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation. 2000;102:2105-2110. PMID: 11044428
9. Chiu PY, Leung HY, Poon MK, Ko KM. Chronic schisandrin B treatment improves mitochondrial antioxidant status and tissue heat shock protein production in various tissues of young adult and middle-aged rats. Biogerontology. 2006;7:199-210. PMID: 16628487
10. Mak DH, Ip SP, Li PC, Poon MK, Ko KM. Effects of Schisandrin B and alpha-tocopherol on lipid peroxidation, in vitro and in vivo. Mol Cell Biochem. 1996;165:161-165. PMID: 8979266
11. Caceres DD, Hancke JL, Burgos RA, Sandberg F, Wikman GK. Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study. Phytomedicine. 1999;6:217-223. PMID: 10589439
12. Xuejiang W, Magara T, Konishi T. Prevention and repair of cerebral ischemia-reperfusion injury by Chinese herbal medicine, shengmai san, in rats. Free RadicRes. 1999;31:449-455. PMID: 10547189
13. Nishida H, Kushida M, Nakajima Y, Ogawa Y, Tatewaki N, Sato S, et al. Amyloid-beta-induced cytotoxicity of PC-12 cell was attenuated by Shengmai-san through redox regulation and outgrowth induction. J Pharmacol Sci. 2007;104:73-81. PMID: 17485916
14. Wang N, Minatoguchi S, Arai M, Uno Y, Nishida Y, Hashimoto K, et al. Sheng-Mai-San is protective against post-ischemic myocardial dysfunction in rats through its opening of the mitochondrial KATP channels. Circ J. 2002;66:763-768. PMID: 12197603
15. Guo LY, Hung TM, Bae KH, Shin EM, Zhou HY, Hong YN, et al. Anti-inflammatory effects of schisandrin isolated from the fruit of SchisandrachinensisBaill. Eur J Pharmacol. 2008;591:293-299. doi: 10. 1016/j.ejphar.2008.06.074 PMID: 18625216
16. Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, Hamamori Y, et al. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 2009;37:5678-5689. doi: 10.1093/nar/gkp593 PMID: 19625493
17. Ip SP, Poon MK, Wu SS, Che CT, Ng KH, Kong YC, et al. Effect of schisandrin Bon hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. PlantaMed. 1995;61:398-401. PMID: 7480197
18. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386-390. PMID: 7477375
19. Chaubey RC, Bhilwade HN, Rajagopalan R, Bannur SV. Gamma ray induced DNA damage in human and mouse leucocytes measured by SCGE-Pro: a software developed for automated image analysis and data processing for Comet assay. Mutat Res. 2001;490:187-197. PMID: 11342244
20. Wold LE, Aberle NS 2nd, Ren J. Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev. 2005;29:294-299. PMID: 15936597
21. Thandavarayan RA, Watanabe K, Ma M, Gurusamy N, Veeraveedu PT, Konishi T, et al. Dominantnegative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol. 2009;297:H911-919. doi: 10.1152/ajpheart.00124.2009 PMID: 19617408
22. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998;82:1298-1305. PMID: 9648726
23. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402-410. PMID: 16157344
24. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation. 2007;116:506-514. PMID: 17638931
25. Thandavarayan RA, Watanabe K, Ma M, Veeraveedu PT, Gurusamy N, Palaniyandi SS, et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol. 2008;75:1797-1806. doi: 10.1016/j.bcp. 2008.02.003 PMID: 18342293
26. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982;126:131-138. PMID: 7181105
27. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229. PMID: 15169927
28. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003;14:2775-2782. PMID: 14569087
29. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314. PMID: 4353012
30. Rinehart JJ, Lewis RP, Balcerzak SP. Adriamycin cardiotoxicity in man. Ann Intern Med. 1974;81:475-478. PMID: 4277990
31. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicininduced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003;63:6602-6606. PMID: 14583452
32. Monti E, Prosperi E, Supino R, Bottiroli G. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res. 1995;15:193-197. PMID: 7733633
33. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J BiolChem. 1996;271:12610-12616. PMID: 8647872
34. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol ExpTher. 2000;294:396-401. PMID: 10871338
35. Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation. 2004;110:2869-2874. PMID: 15505089
36. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension. 1998;31:152-161. PMID: 9453296
37. Tian W, Zhang Z, Cohen DM. MAPK signaling and the kidney. Am J Physiol Renal Physiol. 2000;279:F593-604. PMID: 10997909
38. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998;273:15022-15029. PMID: 9614110
39. Muller E, Burger-Kentischer A, Neuhofer W, Fraek ML, Marz J, Thurau K, et al. Possible involvement of heat shock protein 25 in the angiotensin II-induced glomerular mesangial cell contraction via p38 MAP kinase. J Cell Physiol. 1999;181:462-469. PMID: 10528232
40. Lou H, Danelisen I, Singal PK. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;288:H1925-1930. PMID: 15772336
41. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006;49:2507-2513. PMID: 16937126
42. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol. 2002;97:276-285. PMID: 12111037
43. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004;4:372-377. PMID: 15251131
44. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol. 2006;291:H1273-1280. PMID: 16565313
45. Huang C, Ma WY, Maxiner A, Sun Y, Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem. 1999;274:12229-12235. PMID: 10212189
46. Kishi H, Nakagawa K, Matsumoto M, Suga M, Ando M, Taya Y, et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem. 2001;276:39115-39122. PMID: 11495913
47. Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. MolCell Biochem. 2005;273:25-32. PMID: 16013437
48. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem. 2000;275:33585-33592. PMID: 10899161
49. Konorev EA, Kotamraju S, Zhao H, Kalivendi S, Joseph J, Kalyanaraman B. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic Biol Med. 2002;33:988. PMID: 12361808
50. Kang YJ, Chen Y, Yu A, Voss-Mc Cowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest. 1997;100:1501-1506. PMID: 9294117
51. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Abe Y. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension. 2004;43:117-124. PMID: 14638624
52. Giridharan VV, Thandavarayan RA, Sato S, Ko KM, Konishi T. Prevention of scopolamine-induced memory deficits by schisandrin B, an antioxidant lignan from Schisandra chinensis in mice. Free Radic Res. 2011;45:950-958. doi: 10.3109/10715762.2011.571682 PMID: 21615274